Author

S D Lee

Observed names: S. D. Lee, Scott D. Lee

Institution: University of Washington

Observed institution: University of Washington

OpenAlex ID: A5012805764

Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease

2015 · B. G. Feagan, W. J. Sandborn, et al. · Alimentary Pharmacology & Therapeutics · 113

Ursodiol for all? Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol Use Is Associated With Lower Prevalence of Colonic Neoplasia in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Ann Intern Med 2001;134:89-95

2001 · Scott D. Lee, Christina M. Surawicz · The American Journal of Gastroenterology · 51

GenoType® MTBDRplus assay detection of drug-resistant tuberculosis in routine practice in Korea

2012 · J. Lyu, M-N. Kim, et al. · The International Journal of Tuberculosis and Lung Disease · 30

OP14 Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately to severely active ulcerative colitis: data from the U-ACHIEVE study

2019 · W J Sandborn, S Schreiber, et al. · Journal of Crohn s and Colitis · 9

OP024 Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s disease: the OPERA II study

2018 · G R D’Haens, W Reinisch, et al. · Journal of Crohn s and Colitis · 6

Two-site enzyme immunoassay for alpha-fetoprotein in dried-blood samples collected on filter paper.

1986 · D Tsao, K J Hsiao, et al. · Clinical Chemistry · 6

OP08 Long-term efficacy and pharmacodynamics of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) monoclonal antibody SHP647 in Crohn’s disease: the OPERA II study

2019 · G D’Haens, W Reinisch, et al. · Journal of Crohn s and Colitis · 3

A108 Ustekinumab Iv Induction Results in Crohn’s Disease Symptom Improvement Within the First Week in Anti-tnf Refractory Patients

2018 · W Sandborn, B Yeager, et al. · Journal of the Canadian Association of Gastroenterology · 3

DOP88 Effect of risankizumab on patient-reported outcomes in patients with Crohn’s Disease who had an inadequate response or intolerance to conventional and/or biologic treatments: Results from phase 3 MOTIVATE and ADVANCE trials

2021 · L Peyrin-Biroulet, E Louis, et al. · Journal of Crohn s and Colitis · 1

Works count: 9

Citation count: 222

H-index: 6

I10-index: 3